Alicia Morgans, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Novartis
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Advanced Accelerator Applications
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    BMS
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Dendreon
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Clovis
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Telix
    Date added:
    Date updated:
    04/02/2024

Pages

Return to The Changing Face of Advanced Prostate Cancer 2022 Webcast (2022)